Cohance Lifesciences
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Cohance Lifesciences is currently navigating a transformative phase, marked by the integration of multiple entities into a unified CDMO platform. Management's focus on operational discipline and scaling high-value technology platforms, such as antibody-drug conjugates (ADCs) and oligonucleotides, is crucial for enhancing revenue growth and margins. Despite facing near-term challenges, including a decline in revenue and margin pressure, the outlook for FY27 is cautiously optimistic, supported by a robust pipeline of filings and new customer approvals. Vista's financial outlook reflects moderating revenue growth and ongoing margin pressures, yet the strategic pivot towards high-growth therapeutic areas aligns with the projected industry expansion. The Pharma APIs and CRAMS sector is expected to grow at a CAGR of 10.85%, bolstered by increasing global demand and the shift in supply chains. Key opportunities include the successful execution of the Phase-III pipeline and the integration of the nucleic acid business, while watchpoints include execution risks related to the integration of legacy businesses and potential regulatory impacts. Overall, Cohance's strategic initiatives position it for long-term growth, despite current headwinds
Why We Like This Stock
- Management's strategic pivot towards high-growth, complex therapeutic areas is expected to enhance revenue and margins
- A robust pipeline of filings and new customer approvals supports a cautiously optimistic outlook for FY27
- The Pharma APIs and CRAMS industry is projected to grow significantly, providing a favorable backdrop for Cohance's operations
Things To Watch Out For
- Current revenue growth is moderating, and margins are under pressure due to rising logistics and raw material costs
- Execution risks remain tied to the successful integration of legacy businesses and navigating a volatile macroeconomic environment
- Immediate challenges from deferred shipments and high overheads could impact short-term performance
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,051 | 1,198 | 2,269 | 2,151 | 2,605 |
| Profit Before Tax (Cr.) | 361 | 303 | 237 | 78 | 195 |
| PBT Margin | 34.3% | 25.3% | 10.4% | 3.6% | 7.5% |
| Net Profit (Cr.) | 273 | 226 | 180 | 61 | 128 |
| Earnings Per Share | 7.1 | 6.0 | 5.4 | 1.3 | 3.4 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Goldman Sachs | ▲ Buy | 500 | 06-Aug-2026 |
| ICICI Securities | ▼ Reduce | 365 | 06-Aug-2026 |
| JPMorgan | ► Hold | 490 | 06-Aug-2026 |
| Jeffries | ▼ Underperform | 350 | 06-Aug-2026 |
| Macguire | ▲ Outperform | 1,150 | 06-Aug-2026 |
Company Overview
Show Company Profile
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms (FDE); packaging and clinical trial support services; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.